- Home
- ILPT vs NBTX Comparison
ILPT vs NBTX Comparison
Compare ILPT & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILPT
- NBTX
- Stock Information
- Founded
- ILPT 2017
- NBTX 2003
- Country
- ILPT United States
- NBTX France
- Employees
- ILPT N/A
- NBTX N/A
- Industry
- ILPT Real Estate Investment Trusts
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- ILPT Real Estate
- NBTX Health Care
- Exchange
- ILPT Nasdaq
- NBTX Nasdaq
- Market Cap
- ILPT 232.8M
- NBTX 201.9M
- IPO Year
- ILPT 2018
- NBTX 2020
- Fundamental
- Price
- ILPT $3.73
- NBTX $3.25
- Analyst Decision
- ILPT Buy
- NBTX Strong Buy
- Analyst Count
- ILPT 2
- NBTX 1
- Target Price
- ILPT $10.00
- NBTX $12.00
- AVG Volume (30 Days)
- ILPT 359.3K
- NBTX 42.0K
- Earning Date
- ILPT 02-18-2025
- NBTX 09-18-2024
- Dividend Yield
- ILPT 1.10%
- NBTX N/A
- EPS Growth
- ILPT N/A
- NBTX N/A
- EPS
- ILPT N/A
- NBTX N/A
- Revenue
- ILPT $440,696,000.00
- NBTX $45,220,186.00
- Revenue This Year
- ILPT N/A
- NBTX N/A
- Revenue Next Year
- ILPT $6.87
- NBTX N/A
- P/E Ratio
- ILPT N/A
- NBTX N/A
- Revenue Growth
- ILPT 1.36
- NBTX 526.17
- 52 Week Low
- ILPT $3.15
- NBTX $2.76
- 52 Week High
- ILPT $5.45
- NBTX $8.43
- Technical
- Relative Strength Index (RSI)
- ILPT 58.67
- NBTX 56.43
- Support Level
- ILPT $3.50
- NBTX $2.85
- Resistance Level
- ILPT $3.75
- NBTX $3.07
- Average True Range (ATR)
- ILPT 0.14
- NBTX 0.16
- MACD
- ILPT 0.02
- NBTX 0.05
- Stochastic Oscillator
- ILPT 95.00
- NBTX 73.67
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.